Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NextCure Closes $93 Million B Round Led by China Investors for IO Therapies

publication date: Nov 16, 2018

NextCure of Maryland closed a $93 million series B financing led by China investors Hillhouse Capital and Quan Capital. The financing will support NextCure's next-gen immunomedicines for cancer and other diseases, especially NC318, a first-in-class molecule aimed at S15. S15 is a novel immunomodulatory target associated with lung, ovarian and head and neck cancers. NextCure is also using its FIND-IO™ platform to identify additional targets that impact immune function. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital